Intrinsic Value Partners’s Pfizer PFE Stock Holding History

Intrinsic Value Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,697	Closed	-$218K	–	49
2021 Q4	$218K	Buy	+3,697	New	+$183K	0.23%	45

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Intrinsic Value Partners's PFE Position: Q1 2022 in Review

Intrinsic Value Partners sold out of Pfizer (PFE) in Q1 2022, closing a stake of 3,697 shares — an estimated $218K sold.

Intrinsic Value Partners first reported a position in PFE in Q4 2021 and held it in 1 quarter. The position peaked at $218K in Q4 2021. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

Intrinsic Value Partners reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
Intrinsic Value Partners sold 3,697 Pfizer shares in Q1 2022, an estimated $218K.
Intrinsic Value Partners first reported a position in Pfizer in Q4 2021 and held it in 1 quarter.
Intrinsic Value Partners's Pfizer position peaked at $218K in Q4 2021.
3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on Intrinsic Value Partners's 13F filing for Q1 2022, filed 28 Apr 2022.